Patents by Inventor Xiaozhao Wang

Xiaozhao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
    Publication number: 20180327412
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 15, 2018
    Inventors: Yun-Long Li, Xiaozhao Wang, Joseph Barbosa, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jincong Zhuo
  • Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
    Patent number: 10125133
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: November 13, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
    Patent number: 10112950
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: October 30, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20180244627
    Abstract: The present disclosure relates to heterocyclic compounds, and pharmaceutical compositions of the same, that are modulators/inhibitors of HDACs, such as HDAC8 and are useful in the treatment of HDAC-associated diseases.
    Type: Application
    Filed: August 12, 2016
    Publication date: August 30, 2018
    Inventors: Jun Pan, Xiaozhao Wang, Joseph Barbosa, Wenqing Yao, Yingda Ye
  • Pyrrolopyrimidine derivatives as TAM inhibitors
    Patent number: 10053465
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: August 21, 2018
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
  • Pyrrolotriazine compounds as tam inhibitors
    Patent number: 9981975
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: May 29, 2018
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS
    Publication number: 20170369488
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 28, 2017
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • IMIDAZOPYRAZINES AS LSD1 INHIBITORS
    Publication number: 20170369497
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 28, 2017
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS
    Publication number: 20170362245
    Abstract: The present invention is directed to [1,2,4]triazolo[4,3-a]pyridine and [1,2,4]triazolo[4,3-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: August 7, 2017
    Publication date: December 21, 2017
    Inventors: Liangxing Wu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20170342070
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: April 26, 2017
    Publication date: November 30, 2017
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Ding-Quan Qian, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
  • BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
    Publication number: 20170290839
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 12, 2017
    Inventors: Liang Lu, Bo Shen, Alexander Sokolsky, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Yingda Ye
  • PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
    Publication number: 20170275290
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: March 27, 2017
    Publication date: September 28, 2017
    Inventors: Yun-Long Li, Xiaozhao Wang, Joseph Barbosa, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jincong Zhuo
  • Triazolopyridines and triazolopyrazines as LSD1 inhibitors
    Patent number: 9758523
    Abstract: The present invention is directed to [1,2,4]triazolo[4,3-a]pyridine and [1,2,4]triazolo[4,3-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: September 12, 2017
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 9708318
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 18, 2017
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Bo Shen, Alexander Sokolsky, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Yingda Ye
  • Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
    Patent number: 9695180
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: July 4, 2017
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
    Patent number: 9695167
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: July 4, 2017
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Cycloalkyl-dione derivatives and methods of their use
    Patent number: 9643919
    Abstract: The present invention is directed to compounds of formula I: wherein A is n is 0, 1, or 2; m is 0 or 1; R1 is H or C1-6alkyl and R2 is H, C1-6alkyl, C1-6alkaryl, aryl, or heteroaryl; and X is O or NH. Tautomers, enantiomers, and diastereomers, as well as pharmaceutically acceptable salt forms, of compounds of formula I are also within the scope of the invention. Methods of preparing and using the compounds of formula I are also described.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: May 9, 2017
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Carlo Ballatore, Kurt R. Brunden, Virginia M. Y. Lee, Amos B. Smith, III, John Q. Trojanowski, Xiaozhao Wang
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20170112816
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: October 5, 2016
    Publication date: April 27, 2017
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Ding-Quan Qian, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
  • PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS
    Publication number: 20170057965
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: August 25, 2016
    Publication date: March 2, 2017
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 9493442
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: November 15, 2016
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang